Details for Patent: 11,944,621
Which drugs does patent 11,944,621 protect, and when does it expire?
Patent 11,944,621 protects BRYNOVIN and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 11,944,621
| Title: | Oral gliptin compositions and method for preparation thereof |
| Abstract: | Described is an aqueous liquid oral gliptin composition comprising a gliptin or a pharmaceutically acceptable salt or ester thereof, and an artificial non-sugar alcohol sweetening agent, the solution having a sugar alcohol content of less than 25 w/v %. The composition has an improved taste and stability as compared to known compositions. Also described is a method comprising the steps of heating 80-95 v/v % of the water to 40-65° C., admixing the antioxidant, and, if present, the chelating agent and buffering agent, optionally, cooling down to 25-35° C., admixing sweetener, and, if present, preservative agent, and optionally pH adjusting agent or a portion of the pH adjusting agent, admixing the gliptin, if necessary, adjust the pH to the envisaged value by addition of a pH adjusting agent, admix the thickening agent, optionally in the form of a solution of the thickening agent in a co-solvent, homogenising the obtained mixture, admixing, if present, the wetting agent, if necessary, adjust the final volume by adding from the rest of the water, optionally filter through a 10 μm sieve, and filling in an appropriate container. |
| Inventor(s): | Ioannis Psarrakis, Konstantinos Lioumis |
| Assignee: | Pharma Data Research And Development Single Member SA |
| Application Number: | US17/771,387 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 11,944,621
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | BRYNOVIN | sitagliptin hydrochloride | SOLUTION;ORAL | 219122-001 | Jan 16, 2025 | DISCN | Yes | No | 11,944,621 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,944,621
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3811930 | ⤷ Start Trial | |||
| European Patent Office | 4048230 | ⤷ Start Trial | |||
| Spain | 2961549 | ⤷ Start Trial | |||
| Poland | 4048230 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2021078964 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
